← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2544)
- Hepatic FoxO3 Supports Metabolic Resilience, Attenuates Age-Associated Obesity and Metabolic Dysfunction, and Mitigates Diet-Induced Steatohepatitis. (2026/07/23) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents. (2026/07/23) ♡
- Clinical AI-assisted FXR prioritization and WADDAICA-guided design of a berberine-inspired analogue for MASH: integrated computational and experimental validation. (2026/07/23) ♡
- The METTL3/TRIM37 axis contributes to the progression of non-alcoholic fatty liver disease by promoting CAV1 degradation. (2026/07/22) ♡
- AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models. (2026/07/22) ♡
- Mechanistic study of chenodeoxycholic acid targeting pyruvate kinase to regulate hepatic lipid metabolism. (2026/07/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target. (2026/07/22) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Deep behavioral phenotyping reveals novel features in a mouse model of metabolic dysfunction-associated steatohepatitis. (2026/07/21) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Adipose-Derived Mesenchymal Stem Cells and Their Exosomes Ameliorate Sperm-related Abnormalities, Hormonal Imbalance, and Disrupted Testicular Autophagy in A Diet-Induced Murine Model for Non-Alcoholic Fatty Liver Disease. (2026/07/21) ♡
- Association of neutrophil-to-high-density lipoprotein ratio with all-cause mortality among individuals with non-alcoholic fatty liver disease: the NHANES database prospective cohort study. (2026/07/21) ♡
- An Integrated Analysis to Understand the Dysregulation of Innate Immune Response in Mouse Models of MASLD. (2026/07/21) ♡
- Bovine Milk-Derived Extracellular Vesicles Ameliorate Steatohepatitis by Restoring Gut Barrier in CDA-HFD-Fed Mice. (2026/07/21) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The central role of IL-6 in the differential effects of GLP-1 receptor agonists and metformin across multiple health conditions. (2026/07/21) ♡
- Development and validation of a predictive model for colorectal polyps in patients with NAFLD based on risk factors identified from a meta-analysis. (2026/07/21) ♡
- A precision-constrained framework for evaluating noninvasive biomarkers in MASLD and beyond. (2026/07/20) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study. (2026/07/20) ♡
- Salidroside alleviates metabolic dysfunction-associated steatohepatitis-induced fibrosis by regulating PI3K/AKT/mTOR pathway-mediated hepatocyte mitophagy. (2026/07/20) ♡
- Lasso Regression-based Model for Cross-Sectional Identification of Significant Hepatic Fibrosis in NAFLD LASSO-based identification of hepatic fibrosis in NAFLD. (2026/07/20) ♡
- Integrating fine needle aspiration and single-cell RNA sequencing for studying metabolic dysfunction-associated steatotic liver disease. (2026/07/20) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pharmacological treatment of MASH. (2026/07/17) ♡
- TGR5 activation impairs lung natural killer cell function and promotes bile acid-mediated injury in metabolic liver disease. (2026/07/17) ♡
- Co-production of high-purity floridoside and isofloridoside ameliorates MASH via Parabacteroides goldsteinii-UDCA-FXR enterohepatic axis. (2026/07/17) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Coffee as a polypharmacological modulator of mitochondrial health: from molecular mechanisms to translational implications. (2026/07/17) ♡
- Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study. (2026/07/17) ♡
- Superior inflammatory response and MASH progression in Apoe (-/-) mice compared to wild-type mice: a comprehensive time-course analysis. (2026/07/17) ♡
- Intraoperative liver biopsy during metabolic and bariatric surgery: diagnostic yield, safety, and national trends. (2026/07/17) ♡
- Discovery of Potent and Selective THRβ Agonists Based on an N-Benzoylglycine Scaffold for the Treatment of Metabolic Disorders. (2026/07/16) ♡
- Intestinal Microbiome, Fecal Fermentation Profile, and Health Indices in HIV-Positive Men Versus Normal Controls Without HIV. (2026/07/16) ♡
- ZFP90 Serves as a Transcriptional Brake on NF-κB Signaling to Attenuate Diet-Induced MASLD Progression. (2026/07/16) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Knowledge mapping and bibliometric analysis of metabolic phenotypes in childhood and adolescent obesity: research hotspots and emerging trends from 2000 to 2026. (2026/07/16) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Bixin and Montelukast Combination Mitigates the Progression of MASLD to Cytokine-Driven Inflammatory Stress in an In Vitro Fluid-Dynamic Model. (2026/07/16) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities. (2026/07/16) ♡
- Danggui-Shaoyao-San ameliorates metabolic dysfunction-associated steatohepatitis via suppressing hepatic macrophage NLRP3 inflammasome. (2026/07/15) ♡
- Mechanisms and key active ingredients of HeDan capsules in ameliorating MASLD via bile acid metabolism regulation. (2026/07/15) ♡
- Oleanolic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Ferroptosis through Targeting PTGS2 as a Key Molecular Node and Activating the AMPK/ACC Signaling Pathway. (2026/07/15) ♡
- Identification and Characterization of Novel Anti-inflammatory and Hepatoprotective Properties of Dual-Function Peptides Derived from Jinhua Ham: A Study Integrating Computational Modeling with the cGAS-STING Pathway. (2026/07/15) ♡
- Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk. (2026/07/15) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Targeting hepatic cholesterol sensing to tackle metabolic dysfunction-associated steatohepatitis. (2026/07/15) ♡
- Disruption of branched-chain amino acids homeostasis exacerbates MCD-induced steatohepatitis by amplifying a pro-inflammatory positive feedback loop between hepatocytes and macrophages. (2026/07/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Steatosis to Systemic Metabolic Failure: Classical Pathophysiology, Emerging Systemic Mechanisms and Modifiable Lifestyle Determinants. (2026/07/15) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Metabolic dysfunction-associated steatotic liver disease with alcohol- and iron overload-related cholestatic liver injury: a case report. (2026/07/15) ♡
- Association between the skeletal muscle-to-visceral fat area ratio and liver fibrosis risk in patients with non-alcoholic fatty liver disease: a cross-sectional study. (2026/07/15) ♡
- National divergence in cardio-kidney-metabolic syndrome burden and implications for health policy: a global burden of disease analysis with projections to 2050. (2026/07/15) ♡
- Medical Treatments for Obesity: What Does the Future Have in Store? (2026/07/14) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Effectiveness of dietary modifications in reversing damage induced by high-fat diet in rats. (2026/07/14) ♡
- Diagnostic Utility of Simple Inflammatory Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome in Children with Obesity. (2026/07/14) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. The impact of pectin supplementation on systemic inflammation pathways, gut microbiome, and metabolic health in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A study protocol for a randomised controlled trial. (2026/07/13) ♡
- Genetic or pharmacological inhibition of hepatic TMEM141 attenuates MASH and fibrosis via the ROS-HNF4α signaling pathway. (2026/07/13) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The effect of vitamin D supplementation on the liver function in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis of randomized controlled trials. (2026/07/13) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Eosinophilic Esophagitis and Risk of Non-Alcoholic Fatty Liver Disease and Cirrhosis: A Multi-Center Retrospective Study. (2026/07/13) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.